Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

---------------------------------

Loss before taxes 3,324,241 4,113,231 84,961,498

Future income tax recovery - - (1,115,000)

-------------------------------------------------------------------------

Net loss and comprehensive loss

for the period 3,324,241 4,113,231 83,846,498

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Basic and diluted loss per share (0.08) (0.11)

-----------------------------------------------------------

-----------------------------------------------------------

Weighted average number of shares

(basic and diluted) 41,180,748 38,231,859

-----------------------------------------------------------

-----------------------------------------------------------

See accompanying notes

Oncolytics Biotech Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

Cumulative

from

Three Month Three Month inception

Period Period on April 2,

Ending Ending 1998 to

March 31, March 31, March 31,

2008 2007 2008

$ $ $

------------------------------------------------------------------------

OPERATING ACTIVITIES

Net loss for the period (3,324,241) (4,113,231) (83,846,498)

De
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... 4MD Medical , the leading online medical ... scholarship opportunity for women across the country to earn $2,000 toward academic funding. ... education,” said Rochelle Schwartz, Founder of 4MD Medical and successful business woman that looks ...
(Date:7/7/2015)... July 7, 2015   Moleculera Labs ... matching grant from the Oklahoma Center for the ... supports the development and clinical validation of new ... neuronal antigens in patients experiencing neuropsychiatric disorders such ... are intended to assist physicians in identifying the ...
(Date:7/7/2015)... ... July 07, 2015 , ... Currently deployed within several ... developed to solve many of the complex logistical and data management challenges associated ... clinical sites and/or remote data coordination centers. , CentrePoint drastically reduces personnel ...
(Date:7/6/2015)... Calif. , July 6, 2015  Approximately 1% ... is integrated into their chromosomes. These individuals are three ... new study published in one of the nation,s leading ... of Medicine in Canada.  Photo - ... human herpesvirus 6 (HHV-6) causes roseola (also known as ...
Breaking Biology Technology:4MD Medical Announces $2,000 Scholarship Opportunity in Conjunction with American Business Women’s Association (ABWA) 24MD Medical Announces $2,000 Scholarship Opportunity in Conjunction with American Business Women’s Association (ABWA) 3Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin 2Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin 3ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 3Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3
... July 11 PURE Bioscience (Nasdaq:,PURE) announced today that ... to ring the closing bell at the NASDAQ Stock ... commemorate PURE,s return to the,NASDAQ stock market on April ... live webcast of the closing ceremony will begin at ...
... , The white blood cells in our body ... in leukemia, the formation of white blood cells is ... cells multiply out of control without fully maturing. This ... patients more susceptible to infections. T-ALL, a particular form ...
... July 10 Gen-Probe Incorporated,(Nasdaq: GPRO ) announced ... financial results on Thursday, July 31, 2008 at approximately,4:00 ... by a,conference call at 4:30 p.m. ET. Hank Nordhoff, ... president, finance, and,chief financial officer, will host the call., ...
Cached Biology Technology:PURE Bioscience CEO to Ring NASDAQ Closing Bell 2PURE Bioscience CEO to Ring NASDAQ Closing Bell 3Not the protein, but its location in the cell, determines the onset of leukemia 2Gen-Probe Announces Webcast of Second Quarter 2008 Earnings Conference Call 2
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... market announces a revised version of one of its first 30 ... on CNBC in New York , ... San Francisco metro areas.    , ... to replace all the cards in your wallet and keep your ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2
... of North Carolina at Chapel Hill chemists have ... of creating the world's tiniest manufactured particles for ... human body.Adapting technology pioneered by the electronics industry ... for the first time how to create particles ...
... decision-making tools for public health officials. As demonstrated ... models can be useful in two ways: they ... and they can allow the comparison of alternative ... assumptions that may systematically bias their predictions, say ...
... biology researchers at Virginia Tech have enhanced the abilities ... blows to cancer cells. The man-made molecular complexes enter ... cause the cell to change. The new supermolecules have ... control over the range of light frequencies that can ...
Cached Biology News:Breakthrough: Scientists create world's tiniest organic particles 2Breakthrough: Scientists create world's tiniest organic particles 3Field of beams - Novel system uses polarized light pulses to reveal crop health 2Virginia Tech group adds tools to DNA-targeted anti-cancer drugs 2Virginia Tech group adds tools to DNA-targeted anti-cancer drugs 3
... This kit allows for quick and reproducible ... plate. The system is more reproducible than regular ... the protein A/G agarose without disrupting the agarose ... Catch and Release is reversible, and elution of ...
... Oligo Microarray Kit (V2), 2 x ... characterize expression of many thousands of ... during important biological processes. Each microarray ... known ORFs from the S288C strain ...
... Successful biomarker discovery projects require screening ... to distinguish clinically relevant data from ... Data Manager is now available to ... tracking and data flood inherent to ...
... Immunoprecipitation kit allows a rapid and ... active FLAG-tagged protein. The immunoprecipitation is ... is a highly specific monoclonal antibody ... use of affinity resin allows an ...
Biology Products: